Ryan's District Boards

<p><a href="http://news.yahoo.com/indias-top-court-dismisses-novartis-petition-glivec-patent-052240790--finance.html"><img src="http://l2.yimg.com/bt/api/res/1.2/U5XZHPZ0pX6MBLShgkdeXA--/YXBwaWQ9eW5ld3M7Zmk9ZmlsbDtoPTg2O3E9ODU7dz0xMzA-/http://media.zenfs.com/en_us/News/Reuters/2013-04-01T063818Z_3_CBRE9300EYK00_RTROPTP_2_CBUSINESS-US-INDIA-NOVARTIS-PATENT.JPG" width="130" height="86" alt="A logo is pictured on a building of Swiss drug maker Novartis before its annual general meeting in Pratteln" align="left" title="A logo is pictured on a building of Swiss drug maker Novartis before its annual general meeting in Pratteln" border="0" /></a>By Suchitra Mohanty and Kaustubh Kulkarni NEW DELHI/MUMBAI (Reuters) - India's top court has dismissed Swiss drugmaker Novartis AG's attempt to win patent protection for its cancer drug Glivec, a serious blow to Western pharmaceutical firms who are increasingly focusing on India to drive sales. The decision also sets a benchmark for several intellectual property disputes in India, where many patented drugs are unaffordable for most of its 1.2 billion people, 40 percent of whom earn less than $1.25 a day. ...</p><br clear="all"/>